Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis

23 Sep 2010 • by Natalie Aster

“The development of novel immunosuppressants, coupled with advances in immunology, surgical techniques, donor selection and postoperative care have all contributed to improved outcomes for solid organ transplants, which is now established treatment for organ failure of the kidney, pancreas, liver, heart or lung. While modern immunosuppressive regimes have led to important improvements in short-term graft survival rates, these have not been accompanied by a proportionate increase in long-term graft survival.”

There remains a need for novel agents that can reduce the incidence of acute and chronic rejection: however, achieving large increases in long-term graft survival will be challenging as most causes of graft loss are not due to a lack of efficacy of current immunosuppressants, but are due to medical complications, disease recurrence, non-adherence and most importantly, death with a functioning graft.

The new report "Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis" by Business Insights helps companies active in the transplantation market to increase their success by providing:

An in-depth analysis of the major classes of immunosuppressants, examining how treatment protocols have evolved over the last ten years;

Appraisal of novel compounds in development, highlighting potential clinical advances;

An analysis of the potential impact of regenerative medicine (stem cells) on the market, with drivers and resistors to market growth;

Ten-year forecasts of the number of transplants by organ and country, including estimates of the size of the maintenance populations;

A ten-year forecasts of the number of organ donors, transplants and maintenance populations by organ and country;

Review of the regenerative medicine market, including estimates of the current market size, analysis of over 200 clinical trials and focus on potential applications in cardiovascular, kidney and liver disease;

In-depth analysis of late-stage pipeline products, with discussion of potential clinical advances and how they address current unmet needs;

An overview of organ donation trends including maximum theoretical supply, impact of initiatives to increase the number of donors and how changing donor demographics may impact treatment practice ;

Analysis of US treatment protocols at discharge by drug class and review of graft survival rates by organ including causes of graft loss;

Comparison of business models for cellular therapies and relevance to transplantation medicine.

Report Details

Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis
Published: August 2010
Pages: 120
Price: $3,835

Use the report to answer questions like…

What will overall sales growth be?

Which products could reshape the landscape?

Which areas offer the most substantial growth potential?

How innovative is the market?

Which companies are in the strongest position?

Which smaller companies are attractive for investment?

What are current unmet needs?

What are the greatest areas of uncertainty?

To order the report or ask for free sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.

Mrs. Alla Martin

Tel: +44 208 144 6009

Fax: +44 207 900 3970

[email protected]

marketpublishers.com

Immunosuppressants, Organ Transplants, and the Potential of Regenerative Medicine: Market Size, Competitive Landscape, and Pipeline Analysis

Analytics & News

Weekly Digest